Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin price edges above $83,000 with a 2.29% intraday gain on Oct 19.

Market News
19 Oct 2026
Tokenpost
View Source
Bullish
Bitcoin price edges above $83,000 with a 2.29% intraday gain on Oct 19.

On October 19, Bitcoin (BTC) briefly surpassed the $83,000 mark, trading at $83,036.60, reflecting a 2.29% increase during the day. This rise indicates continued strong interest and momentum in the cryptocurrency market. Investors are watching closely as Bitcoin maintains levels above $83,000, signaling potential further gains or volatility ahead.

Bitcoin's recent trading at $83,036.60 provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang as of Oct 19, 2026 15:02 WIB, 41 out of 50 priced assets rose while 8 fell. Among notable movers, FTM (Fantom) dropped 2.05% to Rp11.382, MANA (Decentraland) also fell 2.05% to Rp1.529 with a typical hold time of 156 days and a slight buy bias, and THETA (Theta Network) declined 2.04% to Rp3.369.

More News

Jyske Bank buys back shares worth DKK 2.15 billion under 2026 repurchase program

Jyske Bank buys back shares worth DKK 2.15 billion under 2026 repurchase program

Jyske Bank has repurchased shares valued at approximately DKK 2.15 billion as part of its ongoing share buyback program running from February 2026 to January 2027. The bank has acquired a total of 2,235,959 treasury shares, representing 3.84% of its ...

Company Fundamentals
Neutral
1 hour ago
Jyske Bank buys back shares worth DKK 2.15 billion, now holding 3.84% of its capital.

Jyske Bank buys back shares worth DKK 2.15 billion, now holding 3.84% of its capital.

Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of mid-October 2026, the bank has repurchased shares worth approximately DKK 2.15 billion at an average price of DK...

Company Fundamentals
Bullish
1 hour ago
Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Oculis completes patient randomization in trial for precision treatment of TNFR1-mediated dry eye disease

Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...

Market News
Bullish
2 hours ago
Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.

Ekalia partners with Telix to boost astatine-211 production in the US for cancer therapy.

Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...

Market News
Bullish
2 hours ago
Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.

Roche unveils pivotal cancer drug data at ESMO 2026, highlighting advances in lung and breast cancer treatments.

At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App